Aquestive has resubmitted its needle-free epinephrine film after an FDA rejection over usability, not efficacy. This FAQ covers what changed.
News|Articles|April 3, 2025
Q1 2025 Recap: Allergy
Author(s)Chelsie Derman
Fact checked by: Victoria Johnson
Q1 2025 allergy updates: FDA approved the first omalizumab biosimilar, and experts shared insights on peanut immunotherapy and food allergy treatments.
Advertisement
Advertisement
The first quarter of 2025 was informative for allergists worldwide, with hundreds attending the annual American Academy of Allergy, Asthma, & Immunology (AAAAI) meeting in San Diego (February 28 – March 3).
Related to this article
What lonvo-z is, how it works, and what a Priority Review designation means for the HAE gene-editing therapy.
The resubmission follows an FDA Complete Response Letter and cites human factors data showing pouch-opening time fell from 17 to 3 seconds.
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
In this Q&A, Alysse Wurcel, MD, translates qualitative barriers into 8 concrete tactics healthcare practices can use to expand penicillin allergy delabeling.
Jim Blando, PhD, of Old Dominion University, explains why allergic patients' lung function dropped most 1 year after wildfire smoke exposure.
A multi-site qualitative study identifies communication, language, and access barriers standing in the way of removing incorrect penicillin allergy labels.
New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.
Advertisement
Advertisement